0000000000899542

AUTHOR

Giuseppa Augello

showing 40 related works from this author

In Human Retinoblastoma Y-79 Cells 3-aminobenzamide induces Differentiation

2006

PARP inhibitorRetinoblastomadifferentiation
researchProduct

GSK-3 in liver diseases: Friend or foe?

2020

Liver diseases, including hepatitis due to hepatitis B or C virus infection, non-alcoholic fatty liver disease, and hepatocellular carcinoma pose major challenges for overall health due to limited curative treatment options. Thus, there is an urgent need to develop new therapeutic strategies for the treatment of these diseases. A better understanding of the signaling pathways involved in the pathogenesis of liver diseases can help to improve the efficacy of emerging therapies, mainly based on pharmacological approaches, which influence one or more specific molecules involved in key signal transduction pathways. These emerging therapies are very promising for the prevention and treatment of …

0301 basic medicineSignaling pathwaysDruggabilityDiseaseBioinformaticsNon-alcoholic fatty liver disease (NAFLD)Glycogen Synthase Kinase 303 medical and health sciences0302 clinical medicineGSK-3Glycogen synthase kinase 3 (GSK-3)AnimalsHumansMedicineHepatitis B virus (HBV)Molecular Targeted TherapyEnzyme InhibitorsHepatocellular carcinoma (HCC)Molecular BiologyHepatitisbusiness.industryLiver DiseasesFatty liverDisease ManagementHepatitis C virus (HCV)Cell BiologyHepatitis Bmedicine.disease030104 developmental biologyGene Expression RegulationMultigene Family030220 oncology & carcinogenesisHepatocellular carcinomaHost-Pathogen InteractionsDisease SusceptibilitySignal transductionbusinessBiomarkersSignal TransductionBiochimica et Biophysica Acta (BBA) - Molecular Cell Research
researchProduct

Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis

2020

Non-alcoholic fatty liver disease (NAFLD) is becoming the main cause of liver disease in Western countries, especially in morbidly obese patients (MOPs). The proprotein convertase subtilisin/kexin type 9 (PCSK9) has been recently studied because of its possible involvement in the pathogenesis of NAFLD, but its role, at least in MOPs, is still controversial. The aim of this study was to clarify the correlation between the circulating levels of the PCSK9 protein (cPCSK9) and its hepatic expression with the severity of liver damage in a population of MOPs with NAFLD undergoing bariatric surgery. PCSK9 mRNA was positively correlated with FASN, PPARγ and PPARα mRNAs, while no significant differe…

AdultMale0301 basic medicinemedicine.medical_specialtySettore MED/06 - Oncologia MedicaPopulationBariatric SurgeryInflammation030204 cardiovascular system & hematologySeverity of Illness IndexPathogenesisNon-alcoholic fatty liver disease (NAFLD)03 medical and health sciencesBallooning degenerationLiver disease0302 clinical medicineInternal medicinemedicineHumansMorbidly obese patients (MOPs)educationMolecular Biologyeducation.field_of_studybusiness.industryPCSK9Fatty liverCell BiologyMiddle AgedLipid Metabolismmedicine.diseaseObesity MorbidFatty LiverProprotein convertase subtilisin/kexin type 9 (PCSK9)030104 developmental biologyEndocrinologyLiverFemaleProprotein Convertase 9medicine.symptomSteatosisbusiness
researchProduct

New landscapes and horizons in hepatocellular carcinoma therapy

2020

Hepatocellular carcinoma (HCC), is the sixth most frequent form of cancer and leads to the fourth highest number of deaths each year. HCC results from a combination of environmental factors and aging as there are driver mutations at oncogenes which occur during aging. Most of HCCs are diagnosed at advanced stage preventing curative therapies. Treatment in advanced stage is a challenging and pressing problem, and novel and well-tolerated therapies are urgently needed. We will discuss further advances beyond sorafenib that target additional signaling pathways and immune checkpoint proteins. The scenario of possible systemic therapies for patients with advanced HCC has changed dramatically in …

OncologySorafenibmedicine.medical_specialtySettore MED/09 - Medicina InternaCarcinoma Hepatocellularmedicine.medical_treatmentAntineoplastic AgentsReviewTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicinemedicineBiomarkers TumorcancerHumansHCC030304 developmental biology0303 health sciencesbusiness.industryagingLiver NeoplasmsCancerCell BiologyImmunotherapyGenetic Therapymedicine.diseaseOmicstargeted therapyImmune checkpointdigestive system diseases3. Good healthGene Expression Regulation Neoplastic030220 oncology & carcinogenesisHepatocellular carcinomaimmunotherapybusinessmedicine.drugPersonal genomicsAging (Albany NY)
researchProduct

NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance

2016

AbstractSorafenib, an oral multikinase inhibitor, is the only approved agent for the treatment of advanced hepatocellular carcinoma (HCC). However, its benefits are modest, and as its mechanisms of action remain elusive, a better understanding of its anticancer effects is needed. Based on our previous study results, we investigated here the implication of the nuclear protein 1 (NUPR1) in HCC and its role in sorafenib treatment. NUPR1 is a stress-inducible protein that is overexpressed in various malignancies, but its role in HCC is not yet fully understood. We found that NUPR1 expression was significantly higher in primary human HCC samples than in the normal liver. Knockdown of NUPR1 signi…

0301 basic medicineMaleCancer ResearchHepatocellular carcinomaCore Binding Factor Alpha 1 Subunit0302 clinical medicineCell MovementBasic Helix-Loop-Helix Transcription FactorsMolecular Targeted TherapyRNA Small InterferingRegulation of gene expressionAged 80 and overGene knockdownRELBLiver NeoplasmsMiddle AgedSorafenib3. Good healthNeoplasm ProteinsSorafenib.Gene Expression Regulation Neoplastic030220 oncology & carcinogenesisGene Knockdown TechniquesOriginal ArticleFemalemedicine.drugSorafenibNiacinamideCarcinoma HepatocellularRUNX2 GeneCell SurvivalIER3ImmunologyDown-RegulationBiology03 medical and health sciencesCellular and Molecular NeuroscienceYoung AdultmedicineGene silencingHumansNeoplasm InvasivenessGene SilencingneoplasmsAgedCell ProliferationCell growthGene Expression ProfilingPhenylurea CompoundsTranscription Factor RelBComputational BiologyMembrane ProteinsCell BiologyNuclear protein-1digestive system diseases030104 developmental biologyDrug Resistance NeoplasmCancer researchApoptosis Regulatory ProteinsTranscriptomeCell Death & Disease
researchProduct

Potential Uses of Olive Oil Secoiridoids for the Prevention and Treatment of Cancer: A Narrative Review of Preclinical Studies

2021

The Mediterranean diet (MD) is a combination of foods mainly rich in antioxidants and anti-inflammatory nutrients that have been shown to have many health-enhancing effects. Extra-virgin olive oil (EVOO) is an important component of the MD. The importance of EVOO can be attributed to phenolic compounds, represented by phenolic alcohols, hydroxytyrosol, and tyrosol, and to secoiridoids, which include oleocanthal, oleacein, oleuropein, and ligstroside (along with the aglycone and glycosidic derivatives of the latter two). Each secoiridoid has been studied and characterized, and their effects on human health have been documented by several studies. Secoiridoids have antioxidant, anti-inflammat…

0301 basic medicineSettore MED/09 - Medicina InternaSettore CHIM/10 - Chimica Degli AlimentiMediterranean dietAnti-Inflammatory AgentsReviewDiet MediterraneanAntioxidantsCyclopentane Monoterpeneslcsh:Chemistrychemistry.chemical_compound0302 clinical medicineGlucosidesNeoplasmsIridoidslcsh:QH301-705.5SpectroscopyTraditional medicineGeneral MedicinePhenylethyl AlcoholComputer Science Applications030220 oncology & carcinogenesissecoiridoidsIridoid GlucosidesAntineoplastic AgentsoleocanthalCatalysisInorganic Chemistry03 medical and health sciencesPhenolsOleuropeinOleocanthalmedicineAnimalsHumanscanceroleaceinPhysical and Theoretical ChemistryOlive OilMolecular BiologyPyransAldehydesOrganic ChemistryCancermedicine.diseaseTyrosol030104 developmental biologyAglyconelcsh:Biology (General)lcsh:QD1-999chemistryoleuropeinligstrosideHydroxytyrosolOlive oilInternational Journal of Molecular Sciences
researchProduct

Electrophoretic Mobility Shift Assay (EMSA) or Gel Shift Assay

2008

EMSA DNA-binding proteinSettore BIO/10 - Biochimica
researchProduct

Cytokine profile of breast cell lines after different radiation doses

2017

Purpose: Ionizing radiation (IR) treatment activates inflammatory processes causing the release of a great amount of molecules able to affect the cell survival. The aim of this study was to analyze the cytokine signature of conditioned medium produced by non-tumorigenic mammary epithelial cell line MCF10A, as well as MCF7 and MDA-MB-231 breast cancer cell lines, after single high doses of IR in order to understand their role in high radiation response. Materials and methods: We performed a cytokine profile of irradiated conditioned media of MCF10A, MCF7 and MDA-MB-231 cell lines treated with 9 or 23 Gy, by Luminex and ELISA analyses. Results: Overall, our results show that both 9 Gy and 23 …

0301 basic medicineIonizing radiationRadiology Nuclear Medicine and ImagingCell SurvivalCytokine profileBreast NeoplasmsInflammationRadiationRadiation ToleranceIonizing radiation03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerCell Line TumormedicinecytokineHumansskin and connective tissue diseasesCell survivalRadiological and Ultrasound TechnologyChemistrybreast cancer cytokines inflammation Ionizing radiation Breast Neoplasms Cell Line Tumor Cell Survival Culture Media Conditioned Dose-Response Relationship Radiation Humans Phenotype Radiation ToleranceDose-Response Relationship Radiationmedicine.diseasecytokinesDose–response relationship030104 developmental biologyPhenotypeCell cultureinflammation030220 oncology & carcinogenesisCulture Media ConditionedImmunologyCancer researchmedicine.symptomBreast NeoplasmHuman
researchProduct

Biocompatible Lipid Nanoparticles as Carriers to Improve Curcumin Efficacy in Ovarian Cancer Treatment

2017

Curcumin is a natural molecule with proved anticancer efficacy on several human cancer cell lines. However, its clinical application has been limited due to its poor bioavailability. Nanocarrier-based drug delivery approaches could make curcumin dispersible in aqueous media, thus overtaking the limits of its low solubility. The aim of this study was to increase the bioavailability and the antitumoral activity of curcumin, by entrapping it into nanostructured lipid carriers (NLCs). For this purpose here we describe the preparation and characterization of three kinds of curcumin-loaded NLCs. The nanosystems allowed the achievement of a controlled release of curcumin, the amounts of curcumin r…

nanostructured lipid carriers curcumin drug release cancer epithelial ovarian cellsCurcuminNanoparticleAdministration Oral02 engineering and technologyPharmacologynanostructured lipid carrier03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug Delivery SystemsNanoparticleSettore BIO/10 - BiochimicamedicineHumanscancerParticle SizeDrug Carrierdrug releaseCell ProliferationOvarian NeoplasmsDrug CarriersOvarian NeoplasmChemistry (all)General ChemistryLipid021001 nanoscience & nanotechnologyBiocompatible materialmedicine.diseaseControlled releaseLipidsBioavailabilitychemistryAgricultural and Biological Sciences (all)Settore CHIM/09 - Farmaceutico Tecnologico Applicativo030220 oncology & carcinogenesisDrug deliveryCurcuminNanoparticlesFemaleNanocarriers0210 nano-technologyGeneral Agricultural and Biological SciencesOvarian cancerDrug Delivery Systemepithelial ovarian cellHuman
researchProduct

Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells

2015

Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of sorafenib was evaluated. The obtained systems showed characteristics suitable as drug delivery systems for the treatment of hepatocellular carcinoma (HCC) through parenteral administration. The use of a mixture between a solid lipid (tripalmitin) with a liquid lipid (Captex 355 EP/NF or Miglyol 812) to prepare NLC systems could give a higher drug loading capacity and a longer term stability during storage than that obtained by using only solid lipids. The obtained nanoparticles showed a nanometer size and high negative zeta potential values. Scansion electron microscopy (SEM) of the sorafenib loaded NLC…

NiacinamideSorafenibDrugCell Survivalmedia_common.quotation_subjectnanostructured lipid carriersPharmaceutical ScienceAntineoplastic AgentsPharmacologyHemolysischemistry.chemical_compoundNanostructured lipid carriers Sorafenib Drug release Angiogenesis inhibitor HepatocarcinomamedicineZeta potentialHumansParticle SizeChromatography High Pressure LiquidTriglyceridesdrug releasemedia_commonDrug CarriersPhenylurea CompoundsHep G2 Cellsmedicine.diseaseLipidsControlled releasedigestive system diseasesIn vitroDrug Liberationangiogenesis inhibitorchemistryhepatocarcinomaSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDelayed-Action PreparationsHepatocellular carcinomaTripalmitinDrug deliveryMicroscopy Electron ScanningNanoparticlessorafenibCaprylatesmedicine.drug
researchProduct

Can Be miR-126-3p a Biomarker of Premature Aging? An Ex Vivo and In Vitro Study in Fabry Disease

2021

Fabry disease (FD) is a lysosomal storage disorder (LSD) characterized by lysosomal accumulation of glycosphingolipids in a wide variety of cytotypes, including endothelial cells (ECs). FD patients experience a significantly reduced life expectancy compared to the general population

SenescencePremature agingAdultMalesenescenceAdolescentPopulationsmall extracellular vesiclesUmbilical veinArticleAndrologyExtracellular VesiclesYoung AdultHUVECIn vivosmall extracellular vesicleHuman Umbilical Vein Endothelial CellsmiR-126-3pMedicineHumanseducationlcsh:QH301-705.5Cellular SenescenceAgedAged 80 and overSettore MED/04 - Patologia Generaleeducation.field_of_studySphingolipidsFabry diseasemicroRNAbusiness.industryagingAging PrematureGeneral MedicineMiddle Agedmedicine.diseaseFabry diseaseendothelial cellsMicroRNAslcsh:Biology (General)endothelial cellBiomarker (medicine)NanoparticlesFemaleGlycolipidsbusinessReactive Oxygen SpeciesEx vivoBiomarkersCells
researchProduct

Cationic solid lipid nanoparticles complexed with genetic material for liver tumor treatment

2015

Concept Gene therapy is a growing field of medicine with great potential for the treatment of several diseases and it is based on the delivery of nucleic acids (DNA, RNA, etc.,) to specific cells. To achieve their therapeutic effects, the nucleic acids need to cross several biological barriers and be protected from the degradation by nucleases, present in biological fluids and intracellular compartments, to successfully gain access to their intracellular targets. To overcome these hurdles, it is necessary to deliver the genetic material with biocompatible carriers able to facilitate its translocation across the cell membranes and protect it from being degraded while circulating in the blood…

siRNADNA plasmidCATIONIC NANOPARTICLEScationic nanoparticles liver gene deliveryHEPATOCARCINOMAGENE DELIVERY
researchProduct

The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment

2020

The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified because of its key role in the regulation of glycogen synthesis. However, it is now well-established that GSK-3 performs critical functions in many cellular processes, such as apoptosis, tumor growth, cell invasion, and metastasis. Aberrant GSK-3 activity has been associated with many human diseases, including cancer, highlighting its potential therapeutic relevance as a target for anticancer therapy. Recently, newly emerging data have demonstrated the pivotal role of GSK-3 in the anticancer immune response. In the last few years, many GSK-3 inhibitors have been developed, and some are currently being te…

medicine.medical_treatmentT cellsReviewmacromolecular substancesNK cellsMetastasisGlycogen Synthase Kinase 3MiceImmune systemCancer immunotherapyGSK-3NeoplasmsPD-1medicineAnimalsHumanscancerGlycogen synthaselcsh:QH301-705.5GSK-3biologyKinasebusiness.industryCancerGeneral MedicineImmunotherapymedicine.diseasesmall molecule inhibitorsDisease Models Animalglycogen synthase kinase-3 (GSK-3)lcsh:Biology (General)Cancer researchbiology.proteinCTLA-4immunotherapybusiness
researchProduct

Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells

2017

AbstractHepatocellular carcinoma (HCC) is one of the common malignancies and is an increasingly important cause of cancer death worldwide. Surgery, chemotherapy, and radiation therapy extend the 5-year survival limit in HCC patients by only 6%. Therefore, there is a need to develop new therapeutic approaches for the treatment of this disease. The orally bioavailable proteasome inhibitor MLN2238 (ixazomib) has been demonstrated to have anticancer activity. In the present study, we investigated the preclinical therapeutic efficacy of MLN2238 in HCC cells through in vitro and in vivo models, and examined its molecular mechanisms of action. MLN2238 inhibited cell viability in human HCC cells He…

Boron Compounds0301 basic medicineCancer ResearchCarcinoma HepatocellularMyeloidCell cycle checkpointImmunologyCellGlycineAntineoplastic AgentsArticleIxazomibAntineoplastic AgentMice03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compound0302 clinical medicinemedicineAnimalsHumansViability assaylcsh:QH573-671Boron CompoundAnimallcsh:Cytologybusiness.industryLiver NeoplasmsCell Biologydigestive system diseases3. Good health030104 developmental biologymedicine.anatomical_structurechemistryLiver NeoplasmCell cultureApoptosis030220 oncology & carcinogenesisProteasome inhibitorCancer researchbusinessProteasome InhibitorsHumanmedicine.drugCell Death & Disease
researchProduct

BeppoSAX serendipitous discovery of the X-ray pulsar SAX J1802.7-2017

2003

We report on the serendipitous discovery of a new X-ray source, SAX J1802.7-2017, ~22' away from the bright X-ray source GX 9+1, during a BeppoSAX observation of the latter source on 2001 September 16-20. SAX J1802.7-2017 remained undetected in the first 50 ks of observation; the source count rate in the following ~300 ks ranged between 0.04 c/s and 0.28 c/s, corresponding to an averaged 0.1-10 keV flux of 3.6 10^{-11} ergs cm^{-2} s^{-1}. We performed a timing analysis and found that SAX J1802.7-2017 has a pulse period of 139.612 s, a projected semimajor axis of a_x sin i ~ 70 lt-s, an orbital period of ~4.6 days, and a mass function f(M) ~ 17 Msun. The new source is thus an accreting X-ra…

PhysicsSemi-major axisAstrophysics (astro-ph)FluxFOS: Physical sciencesAstronomy and AstrophysicsAstrophysicsAstrophysicsOrbital periodPulse periodSettore FIS/05 - Astronomia E AstrofisicaPulsarSpace and Planetary ScienceHigh massStars: Pulsars: General Stars: Pulsars: Individual: Alphanumeric: SAX J1802.7-2017 Stars: Magnetic Fields Stars: Neutron X-Rays: BinariesX-ray pulsar
researchProduct

Delivery of shNupr1 plasmid by solid lipid nanoparticles reduces the expression of Nupr1 gene in hepatocellular carcinoma cells

2015

shNupr1 plasmid gene delivery hepatocellular carcinoma
researchProduct

miR-126-3p and miR-21-5p as Hallmarks of Bio-Positive Ageing; Correlation Analysis and Machine Learning Prediction in Young to Ultra-Centenarian Sici…

2022

Human ageing can be characterized by a profile of circulating microRNAs (miRNAs), which are potentially predictors of biological age. They can be used as a biomarker of risk for age-related inflammatory outcomes, and senescent endothelial cells (ECs) have emerged as a possible source of circulating miRNAs. In this paper, a panel of four circulating miRNAs including miR-146a-5p, miR-126-3p, miR-21-5p, and miR-181a-5p, involved in several pathways related to inflammation, and ECs senescence that seem to be characteristic of the healthy ageing phenotype. The circulating levels of these miRNAs were determined in 78 healthy subjects aged between 22 to 111 years. Contextually, extracellular miR-1…

Aged 80 and overSettore MED/04 - Patologia Generaleageing; inflamm-ageing; endothelial senescence; longevity; miRNAsagingEndothelial Cellsinflamm-ageingGeneral Medicineinflamm-agingMachine LearningMicroRNAslongevityageingendothelial senescenceCentenariansmiRNAsHumansCirculating MicroRNABiomarkersCells; Volume 11; Issue 9; Pages: 1505
researchProduct

A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells

2016

Phosphatase and tensin homolog (PTEN) gene is considered a tumor suppressor gene. However, PTEN mutations rarely occur in hepatocellular carcinoma (HCC), whereas heterozygosity of PTEN, resulting in reduced PTEN expression, has been observed in 32–44% of HCC patients. In the present study, we investigated the effects of the small molecule PTEN inhibitor VO-OHpic in HCC cells. VO-OHpic inhibited cell viability, cell proliferation and colony formation, and induced senescence-associated β-galactosidase activity in Hep3B (low PTEN expression) and to a lesser extent in PLC/PRF/5 (high PTEN expression) cells, but not in PTEN-negative SNU475 cells. VO-OHpic synergistically inhibited cell viability…

0301 basic medicineMAPK/ERK pathwayPTENCarcinoma HepatocellularsenescenceTumor suppressor geneCell SurvivalMicePhosphatidylinositol 3-Kinases03 medical and health sciences0302 clinical medicineReportOrganometallic CompoundsAnimalsHumansPTENTensinViability assayHCCProtein kinase BMolecular BiologyPI3K/AKT/mTOR pathwayCell ProliferationbiologyCell growthTOR Serine-Threonine KinasesAKTLiver NeoplasmsPTEN PhosphohydrolaseCell BiologySorafenibXenograft Model Antitumor Assaysdigestive system diseasesVO-OHpicGene Expression Regulation Neoplastic030104 developmental biology030220 oncology & carcinogenesisbiology.proteinCancer researchSignal TransductionDevelopmental Biology
researchProduct

Identification of an LPS-Induced Chemo-Attractive Peptide from Ciona robusta

2020

Background: Previously published work has demonstrated that the LPS injection of Ciona robusta leads to the overexpression of a truncated form of an immune-related mRNA (C8short) by means of Ciona robusta (CR) alternative polyadenylation (APA) (CR-APA). Methods: The 3D structure of the C8short-derived Ciona robusta chemo-attractive peptide (CrCP) was evaluated by homology modeling. The biological activity of the CrCP was studied in vitro using a primary human dermal cell line (HuDe). Real-Time PCR was used to investigate the expression levels of genes involved in cell motility. NF-&kappa

In silicoPharmaceutical ScienceMotilitychemoattractive peptide03 medical and health sciencesAdapter molecule crk0302 clinical medicineWestern blotDrug DiscoverymedicineNF-kBCiona robustaPharmacology Toxicology and Pharmaceutics (miscellaneous)<i>Ciona robusta</i>lcsh:QH301-705.5030304 developmental biology0303 health sciencesmedicine.diagnostic_testChemistryfungiIn vitro3D modellingCell biologyBlotlcsh:Biology (General)Cell cultureinflammation030220 oncology & carcinogenesisSignal transductionCiona robusta; inflammation; chemoattractive peptide; NF-kB; 3D modellingMarine Drugs
researchProduct

Delivery of shRNA plasmid DNA by cationic solid lipid nanoparticles for gene silencing in human hepatocarcinoma cells

2015

hepatocarcinoma cationic nanoparticles
researchProduct

Paclitaxel and beta-lapachone synergistically induce apoptosis in human retinoblastoma Y79 cells by downregulating the levels of phospho-Akt.

2009

Paclitaxel (PTX) and beta-lapachone (LPC) are naturally occurring compounds that have shown a large spectrum of anticancer activity. In this article we show for the first time that PTX/LPC combination induces potent synergistic apoptotic effects in human retinoblastoma Y79 cells. Combination of suboptimal doses of PTX (0.3 nM) and LPC (1.5 microM) caused biochemical and morphological signs of apoptosis at 48 h of treatment. These effects were accompanied by potent lowering in inhibitor of apoptosis proteins and by activation of Bid and caspases 3 and 6 with lamin B and PARP breakdown. PTX/LPC combination acted by favoring p53 stabilization through a lowering in p-Akt levels and in ps166-MDM…

Time FactorsPhysiologyClinical BiochemistryApoptosisInhibitor of Apoptosis ProteinsWortmanninchemistry.chemical_compoundSettore BIO/10 - BiochimicaAntineoplastic Combined Chemotherapy ProtocolsPhosphorylationCaspasebiologyCaspase 6Lamin Type BCaspase 3Protein StabilityRetinoblastomaDrug SynergismProto-Oncogene Proteins c-mdm2TransfectionBiochemistrylipids (amino acids peptides and proteins)Poly(ADP-ribose) PolymerasesWortmanninBH3 Interacting Domain Death Agonist Proteinretinoblastoma survival factors apoptosisPaclitaxelCell SurvivalPoly ADP ribose polymeraseActive Transport Cell NucleusDown-RegulationInhibitor of apoptosisTransfectionCell Line TumorHumansProtein kinase BProtein Kinase InhibitorsCell NucleusDose-Response Relationship DrugCell BiologyAntineoplastic Agents PhytogenicAndrostadieneschemistryCell cultureApoptosisbiology.proteinCancer researchTumor Suppressor Protein p53Proto-Oncogene Proteins c-aktNaphthoquinonesJournal of cellular physiology
researchProduct

Two single nucleotide polymorphisms in the MICA gene and sMICA plasma levels are associated with hepatocellular carcinoma development in an Italian p…

2017

Background &amp; Aims: We investigated the relationships between MICA polymorphisms, sMICA levels and hepatocellular carcinoma (HCC) risk in HCC patients with chronic hepatitis C virus (HCV) infection. Methods.154 HCV-related HCC cases, 93 HCV-related liver cirrhosis (LC) cases and 244 healthy controls were genotyped using KASPTM SNP method. Levels of plasma soluble MICA (sMICA) were measured in 132 HCC, 90 LC patients and in 78 controls. Results. Genotyping of MICA rs2596542 showed that G/G genotype was significantly more frequent in HCC than in controls and in HCC than in LC patients. As for MICA rs2596538 allele C and C/C genotype were significantly more frequent in HCC than in controls …

Settore MED/09 - Medicina InternaHCC liver cirrhosis HCV single nucleotide polymorphisms
researchProduct

Cationic Solid Lipid Nanoparticles (SLN) for shNupr1 plasmid delivery in the treatment of hepatocellular carcinoma (HCC)

2016

hepatocellular carcinoma plasmid cationic nanoparticles
researchProduct

Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma

2017

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world, and represents the second most frequently cancer and third most common cause of death from cancer worldwide. At advanced stage, HCC is a highly aggressive tumor with a poor prognosis and with very limited response to common therapies. Therefore, there is still the need for new effective and well-tolerated therapeutic strategies. Molecular-targeted therapies hold promise for HCC treatment. One promising molecular target is the multifunctional serine/threonine kinase glycogen synthase kinase 3 (GSK-3). The roles of GSK-3β in HCC remain controversial, several studies suggested a possible role of GSK-3β as a tumor …

0301 basic medicinePathologymedicine.medical_specialtyCancer ResearchCarcinoma HepatocellularEpithelial-Mesenchymal TransitionTumor suppressor geneAntineoplastic Agentsmacromolecular substancesBiologyMetastasisGlycogen Synthase Kinase 303 medical and health sciencesWnt0302 clinical medicineGeneticTransforming Growth Factor betaGSK-3GeneticsmedicineHumansHedgehog ProteinsMolecular Targeted TherapyInsulin-Like Growth Factor IHCCIGFβ-cateninGlycogen synthaseHedgehogMolecular Biologybeta CateninGSK-3Glycogen Synthase Kinase 3 betaReceptors NotchLiver NeoplasmsWnt signaling pathwayCancermedicine.diseaseSurvival Analysisdigestive system diseasesGene Expression Regulation Neoplastic030104 developmental biology030220 oncology & carcinogenesisHepatocellular carcinomabiology.proteinCancer researchMolecular MedicineHedgehogSignal Transduction
researchProduct

PROLONGED TREATMENT OF HUMAN OSTEOSARCOMA MG63 CELLS WITH 3AB INDUCES THE PRODUCTION OF TUMOR INITIATING CELLS.

2008

osteosarcoma cells PARP inhibitorsSettore BIO/10 - Biochimica
researchProduct

RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma

2019

Introduction: Hepatocellular carcinoma (HCC) is a significant problem globally because of viral infections and the increasing incidence of obesity and fatty liver disease. However, it is difficult to treat because its inherent genetic heterogeneity results in activation of numerous signaling pathways. Kinases have been targeted for decades with varying results, but the development of therapeutic resistance is a major challenge. Areas covered: The key roles of the RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1, TP53 microRNAs (miRs) as therapeutic targets are discussed and we suggests novel approaches for targeting miRs or their downstream targets to combat HCC. We performed literature searches using…

0301 basic medicineMAPK/ERK pathwayCarcinoma HepatocellularHepatocellular carcinmamedicine.medical_treatmentClinical BiochemistryAntineoplastic AgentsmTORC1signal transduction inhibitorsTargeted therapy03 medical and health sciences0302 clinical medicineDrug DiscoverymicroRNAmedicinePTENAnimalsHumanscancerMolecular Targeted TherapyTP53HCCRAS/RAF/MEK/ERKProtein kinase BPI3K/AKT/mTOR pathwaymiRNAPharmacologybiologybusiness.industryKinaseLiver NeoplasmsMirhepatocellular carcinomatargeted therapyGene Expression Regulation NeoplasticMicroRNAssignal transduction inhibitor030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisbiology.proteinCancer researchMolecular MedicinePI3K/PTEN/AKTbusinessSignal Transduction
researchProduct

Association between MICA Gene Variants and the Risk of Hepatitis C Virus-Induced Hepatocellular Cancer in a Sicilian Population Sample

2018

There are currently no biomarkers that predict hepatocellular carcinoma (HCC) risk in patients with hepatitis C virus (HCV)-related cirrhosis. We investigated the relationships among major histocompatibility complex (MHC) class I chain-related gene A (MICA) polymorphisms, plasma levels of soluble MICA (sMICA), and HCC risk in patients with HCV-related HCC. One hundred fifty-four HCV-related HCC patients, 93 HCV-related liver cirrhosis (LC) cases, and 244 healthy controls, all sampled from the native Sicilian population, were genotyped using the KASP™ single-nucleotide polymorphism genotyping method. The MICA rs2596542 polymorphism showed that the G/G genotype was significantly more frequent…

Liver CirrhosisMale0301 basic medicineGenetic LinkageHepacivirusHepacivirusmedicine.disease_causeGastroenterologyBiochemistryLinkage DisequilibriumMiceLiver disease0302 clinical medicineGenotypeOdds RatioAged 80 and overeducation.field_of_studybiologyHepatitis Chepatocellular carcinomaMiddle AgedHepatitis CItalyPopulation Surveillance030220 oncology & carcinogenesisHepatocellular carcinomagenetic association studyHCVMolecular MedicineFemaleDisease SusceptibilityCell-Free Nucleic AcidsBiotechnologymedicine.medical_specialtyCarcinoma HepatocellularGenotypeHepatitis C virusPopulation03 medical and health sciencesInternal medicinemedicineGeneticsAnimalsHumanseducationMolecular BiologyAllelesAgedbusiness.industryliver cirrhosiDecision TreesHistocompatibility Antigens Class IGenetic VariationOdds ratiomedicine.diseasebiology.organism_classificationdigestive system diseases030104 developmental biologyMICAbusinessBiomarkers
researchProduct

Outcome predictors in SARS-CoV-2 disease (COVID-19): The prominent role of IL-6 levels and an IL-6 gene polymorphism in a western Sicilian population

2022

Microbiology (medical)Polymorphism GeneticSettore MED/09 - Medicina InternaInfectious DiseasesCOVID-19.Interleukin-6SARS-CoV-2HumanJournal of Infection
researchProduct

Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation

2017

The beneficial health properties of the Mediterranean diet are well recognized. The principle source of fat in Mediterranean diet is extra-virgin olive oil (EVOO). Oleocanthal (OC) is a naturally occurring minor phenolic compound isolated from EVOO, which has shown a potent anti-inflammatory activity, by means of its ability to inhibit the cyclooxygenase (COX) enzymes COX-1 and COX-2. A large body of evidence indicates that phenols exhibit anticancer activities. The aim of the present study was to evaluate the potential anticancer effects of OC in hepatocellular carcinoma (HCC) and colorectal carcinoma (CRC) models. A panel of human HCC (HepG2, Huh7, Hep3B and PLC/PRF/5) and CRC (HT29, SW48…

0301 basic medicineCancer ResearchCarcinoma HepatocellularHepatocellular carcinomaOleocanthalExtra-virgin olive oilCellApoptosisCyclopentane Monoterpenes03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhenolsOleocanthalmedicineHumansCyclooxygenase InhibitorsViability assayOlive OilCaspaseCell ProliferationAldehydesbiologyCell growthLiver NeoplasmsApoptosiHep G2 CellsCell cycledigestive system diseasesColorectal carcinoma030104 developmental biologymedicine.anatomical_structureOncologychemistryApoptosisCell culture030220 oncology & carcinogenesisImmunologybiology.proteinCancer researchReactive oxygen specieColorectal NeoplasmsReactive Oxygen SpeciesDNA DamageInternational Journal of Oncology
researchProduct

NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response

2021

AbstractBackground and AimsNon-alcoholic fatty liver disease and related hepatic syndromes affect up to one third of the adult population. The molecular mechanisms underlying NAFL etiology remain elusive. Nuclear Protein 1 (NUPR1) expression increases upon cell injury in all organs and recently we report its active participation in the activation of the Unfolded Protein Response (UPR). The UPR typically maintains protein homeostasis, but downstream mediators of the pathway regulate metabolic functions, including lipid metabolism. NUPR1 and UPR increase have been reported in obesity and liver pathologies and the goal of this study was to investigate the roles of NUPR1 in this context.Methods…

0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaPPAR-a signalling UPRPeroxisome proliferator-activated receptorContext (language use)UPRDiet High-FatBiochemistry03 medical and health sciencesLiver diseaseMice0302 clinical medicineInternal medicineCell Line TumorGeneticsmedicineBasic Helix-Loop-Helix Transcription FactorsAnimalsHomeostasisHumansMolecular Biologychemistry.chemical_classificationbusiness.industryEndoplasmic reticulumFatty liverNASHLipid metabolismlipotoxicitymedicine.diseaseEndoplasmic Reticulum StressLipid MetabolismNeoplasm Proteins030104 developmental biologyEndocrinologychemistryLipotoxicityLiverNAFLKnockout mouseUnfolded protein responseUnfolded Protein ResponsePPAR-a signallingSteatosisSteatohepatitisbusiness030217 neurology & neurosurgeryNUPR1Biotechnology
researchProduct

Western Blotting Analysis

2008

Protein Analysis
researchProduct

Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma

2018

Hepatocellular carcinoma (HCC) is a highly malignant tumor that responds very poorly to existing therapies, most probably due to its extraordinary inter- and intra-tumor molecular heterogeneity. The modest therapeutic response to molecular targeted agents underlines the need for new therapeutic approaches for HCC. In our study, we took advantage of well-characterized human HCC cell lines, differing in transcriptomic subtypes, DNA mutation and amplification alterations, reflecting the heterogeneity of primary HCCs, to provide a preclinical evaluation of the specific heat shock protein 90 (HSP90) inhibitor AUY922 (luminespib). Indeed, HSP90 is highly expressed in different tumor types, but it…

p53MaleCancer ResearchCellTranscriptome0302 clinical medicineHCCbeta CateninAged 80 and overLuminespibAUY922Liver NeoplasmsHep G2 CellsSorafenibMiddle AgedUp-RegulationGene Expression Regulation Neoplasticmedicine.anatomical_structureOncologyCaspases030220 oncology & carcinogenesisHepatocellular carcinomaFemaleNUPR1medicine.drugAdultSorafenibCarcinoma Hepatocellularβ-CateninMice NudeAntineoplastic AgentsSmall Molecule Libraries03 medical and health sciencesDownregulation and upregulationIn vivoCell Line TumormedicineHSP90AnimalsHumansHSP90 Heat-Shock ProteinsAgedCell growthbusiness.industryMcl-1IsoxazolesResorcinolsHCCSmedicine.diseasedigestive system diseasesMutationCancer researchTranscriptomebusinessInternational Journal of Cancer
researchProduct

The clinical impact of an extra virgin olive oil enriched mediterranean diet on metabolic syndrome: Lights and shadows of a nutraceutical approach

2022

For years it has been established that the only truly effective treatment of metabolic syndrome (MS) is lifestyle modification to prevent its cardiovascular (e.g., coronary artery disease and atherosclerosis), metabolic (e.g., diabetes mellitus), and hepatic (e.g., steatosis and non-alcoholic steatohepatitis) complications. The focal points of this approach are to increase physical activity and intake of a diet characterized by high quantities of fruits, vegetables, grains, fish, and low-fat dairy products, the so called mediterranean diet (MD); however, the added value of MD is the presence of extra virgin olive oil (EVOO), a healthy food with a high content of monounsaturated fatty acids,…

functional foodSettore MED/09 - Medicina InternaNutrition and Dieteticsnutraceuticals.cardiovascular diseaseinsulin resistanceEndocrinology Diabetes and Metabolismextra virgin olive oil (EVOO)metabolic syndromeFood ScienceFrontiers in Nutrition
researchProduct

From Targets to Targeted Therapies in Hepatocellular Carcinoma

2014

MAPK/ERK pathwaybusiness.industrymedicine.medical_treatmentRPTORmedicine.diseaseBiochemistryTargeted therapyHepatocellular carcinomaGeneticsCancer researchMolecular MedicineMedicinebusinessBiotechnologyForum on Immunopathological Diseases and Therapeutics
researchProduct

The New X-Ray Pulsar J1802.7-2017 Observed by BeppoSAX

2004

We report on the serendipitous discovery of a new X-ray source, SAX J1802.7-2017, ~ 22' away from the bright X-ray source GX 9+l, during a BeppoSAX observation of the latter source on 2001 September 16-20.The source was outside the FOV of the BeppoSAX/ LECS. We have verified its presence in both the MECS2 and MECS3 images, which probably excludes that this was a ghost image of a source outside the MECS FOV. Moreover, we can be sure that the source was within the PDS FOV. because the source X-ray pulsations were detected also in the PDS data (see below). We searched for known X-ray sources in a circular region of 30' centered at GX 9+1 in the SIMBAD data base. We found no known sources with …

PhysicsPosition (vector)SIMBADAstrophysicsBase (topology)X-ray pulsarInternational Astronomical Union Colloquium
researchProduct

The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods

2020

Background. Bariatric surgery patients have a higher prevalence of nonalcoholic fatty liver (NAFL) than the general population; however, its assessment and the accurate staging of fibrosis are often complicated because noninvasive tests are not very accurate in patients with morbid obesity, and liver biopsy cannot be performed as a routine exam. The aim of this study was to evaluate (A) the histological prevalence of NAFL, nonalcoholic steatohepatitis (NASH), and fibrosis in patients undergoing bariatric surgery; (B) the reliability of ultrasound (US) in diagnosing NAFL; and (C) the reliability of various fibrosis scoring systems for defining fibrosis. Methods. US and intraoperative liver b…

AdultMalemedicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaArticle SubjectPopulationBariatric SurgeryPrevalence NAFLD Fibrosis Bariatric Surgery Non invasive diagnosis UltrasoundGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseDiabetes mellitusNonalcoholic fatty liver diseasemedicinePrevalenceHumansObesityeducationNonalcoholic steatohepatitis (NASH)Retrospective StudiesUltrasonographyeducation.field_of_studyGeneral Immunology and Microbiologymedicine.diagnostic_testbusiness.industryFatty liverRRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseFibrosisSurgeryObesity Morbidultrasound (US)ROC Curve030220 oncology & carcinogenesisLiver biopsyMedicine030211 gastroenterology & hepatologyFemalebusinessResearch ArticleNonalcoholic fatty liver disease (NAFLD)BioMed Research International
researchProduct

Hepatocellular Carcinoma: A Difficult Cancer to Treat

2021

Hepatocellular carcinoma (HCC) is a very peculiar cancer because it presents several molecular alterations linked to the activation of survival and antiapoptotic signal pathways that are protein in form and not easily targetable by even the newest targeted therapies. In addition, it is almost always a consequence of liver cirrhosis, a serious disease condition in which several drugs are often not tolerated. This is why the study of HCC was such a challenge for Professor Natale D'Alessandro, to whom this work is dedicated, during the latter years of his career. The aim of this review is to summarize studies on different molecules involved in the development, progression, and chemoresistance …

Liver CirrhosisCancer ResearchCarcinoma HepatocellularCirrhosisDruggabilityDrug resistanceNuclear factor κbDiseaseYY1medicineHumansInterleukin 6IL-6drug resistancebiologybusiness.industryLiver NeoplasmsCancerhepatocellular carcinomamedicine.diseasedigestive system diseasescyclooxygenasesHepatocellular carcinomaNF-?Bbiology.proteinCancer researchEpatocarcinoma ciclossigenasi NF-kB IL-6 farmacoresistenza YY1businessSignal TransductionCritical Reviews™ in Oncogenesis
researchProduct

The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma

2021

The multikinase inhibitor sorafenib was the first drug approved by the FDA for treating patients with advanced hepatocellular carcinoma (HCC). However, sorafenib resistance remains a major challenge for improving the effectiveness of HCC treatment. Previously, we identified several genes modulated after sorafenib treatment of human HCC cells, including the stress-inducible nuclear protein 1 (NUPR1) gene. Multiple studies have shown that NUPR1 regulates autophagy, apoptosis, and chemoresistance. Here, we demonstrate that treatment of HCC cells with sorafenib resulted in the activation of autophagic flux. NUPR1 knock-down (KD) in HCC cells was associated with increased p62 expression, suggest…

SorafenibCancer ResearchCarcinoma HepatocellularSettore MED/09 - Medicina InternaHepatocellular carcinomap73Mice NudeApoptosisSettore BIO/11 - Biologia MolecolareMiceNSC5594In vivoPumaBasic Helix-Loop-Helix Transcription FactorsmedicineAutophagyNSC5994AnimalsHumansGene silencingneoplasmsbiologyActivator (genetics)business.industryLiver NeoplasmsAutophagyApoptosiTumor Protein p73Hep G2 CellsSorafenibbiology.organism_classificationmedicine.diseasedigestive system diseasesNeoplasm ProteinsOncologyDrug Resistance NeoplasmApoptosisHepatocellular carcinomaCancer researchFemalebusinessNUPR1medicine.drug
researchProduct

In human retinoblastoma Y79 cells okadaic acid-parthenolide co-treatment induces synergistic apoptotic effects, with PTEN as a key player.

2013

Retinoblastoma is the most common intraocular malignancy of childhood. In developing countries, treatment is limited, long-term survival rates are low and current chemotherapy causes significant morbidity to pediatric patients and significantly limits dosing. Therefore there is an urgent need to identify new therapeutic strategies to improve the clinical outcome of patients with retinoblastoma. here, we investigated the effects of two natural compounds okadaic acid (OKa) and parthenolide (PN) on human retinoblastoma Y79 cells. For the first time we showed that OKa/PN combination at subtoxic doses induces potent synergistic apoptotic effects accompanied by lowering in p-akt levels, increasin…

Cancer ResearchCell SurvivalGene ExpressionAntineoplastic AgentsApoptosisBiologychemistry.chemical_compoundSettore BIO/10 - BiochimicaCell Line TumorOkadaic AcidmedicinePTENCytotoxic T cellHumansParthenolideViability assayProtein kinase BCell ShapePharmacologyRetinoblastomaPTEN PhosphohydrolaseRetinoblastomaDrug SynergismProto-Oncogene Proteins c-mdm2Okadaic acidmedicine.diseaseGlutathioneOxidative StressOncologychemistryApoptosisCancer researchbiology.proteinMolecular Medicineretinoblastoma Y79 cells synergistic apoptotic effects oxidative stress natural drugs PTEN/Akt/Mdm2/p53 pathway parthenolide okadaic acid.Drug Screening Assays AntitumorTumor Suppressor Protein p53Reactive Oxygen SpeciesProtein Processing Post-TranslationalProto-Oncogene Proteins c-aktSesquiterpenesResearch PaperCancer biologytherapy
researchProduct

A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells

2016

Phosphatase and tensin homolog (PTEN) gene is considered a tumor suppressor gene. However, PTEN mutations rarely occur in hepatocellular carcinoma (HCC), whereas heterozygosity of PTEN, resulting in reduced PTEN expression, has been observed in 32–44% of HCC patients. In the present study, we investigated the effects of the small molecule PTEN inhibitor VO-OHpic in HCC cells. VO-OHpic inhibited cell viability, cell proliferation and colony formation, and induced senescence-associated β-galactosidase activity in Hep3B (low PTEN expression) and to a lesser extent in PLC/PRF/5 (high PTEN expression) cells, but not in PTEN-negative SNU475 cells. VO-OHpic synergistically inhibited cell viability…

digestive system diseases
researchProduct